A randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy

EURAMOS I

Open-label, randomized phase III multicenter trial

• Age <40 years
• Histological evidence of high grade osteosarcoma of the extremity or axial skeleton including those arising as second malignancies
• Resectable disease
• Normal bone marrow, hepatic, cardiac and renal function
• Adequate performance status (Karnofsky score ≥60 or WHO ≤2 for patients aged ≥16, or Lansky score ≥60  if age <16.  Patients with a pathologic fracture are eligible if able to undergo treatment.

MAP

MAPifn

MAP

MAPIE

–